The FDA recently passed a new policy framework governing the development and oversight of regenerative medicine. Attorney Michael Werner discussed these new policies and what they mean for the industry at large on an episode of RARECast.
Please note that email communications to the firm through this website do not create an attorney-client relationship between you and the firm. Do not send any privileged or confidential information to the firm through this website. Click "accept" below to confirm that you have read and understand this notice.